A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee
| dc.contributor.author | Mino-Kenudson M. | |
| dc.contributor.author | Berezowska S. | |
| dc.contributor.author | Minami Y. | |
| dc.contributor.author | Chen S. | |
| dc.contributor.author | Ray M.A. | |
| dc.contributor.author | Rerkpichaisuth V. | |
| dc.contributor.author | Hashisako M. | |
| dc.contributor.author | Losmanova T. | |
| dc.contributor.author | Hayashi T. | |
| dc.contributor.author | Shim H.S. | |
| dc.contributor.author | Righi L. | |
| dc.contributor.author | Gagné A. | |
| dc.contributor.author | Kim T.J. | |
| dc.contributor.author | Bubendorf L. | |
| dc.contributor.author | Lopez-Rios F. | |
| dc.contributor.author | Matsubara D. | |
| dc.contributor.author | von der Thüsen J. | |
| dc.contributor.author | Lantuejoul S. | |
| dc.contributor.author | Roden A.C. | |
| dc.contributor.author | Nicholson A. | |
| dc.contributor.author | Jain D. | |
| dc.contributor.author | Han Y. | |
| dc.contributor.author | Wynes M.W. | |
| dc.contributor.author | Dacic S. | |
| dc.contributor.author | Smeltzer M.P. | |
| dc.contributor.author | Cooper W.A. | |
| dc.contributor.author | Papotti M.G. | |
| dc.contributor.correspondence | Mino-Kenudson M. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2025-12-13T18:18:27Z | |
| dc.date.available | 2025-12-13T18:18:27Z | |
| dc.date.issued | 2025-01-01 | |
| dc.description.abstract | Introduction: Tumor grading informs therapy and patient management across many organs, yet no consensus exists for grading invasive squamous cell carcinoma of the lung (LUSC). This study aimed to develop a globally applicable grading system using international cohorts. Methods: Histologic features, including tumor budding, smallest tumor nest size, nuclear size, and tumor spread through air spaces (STAS), were evaluated in two training sets comprising 262 and 427 LUSCs resected without neoadjuvant therapy from three institutions. Kaplan-Meier and Cox proportional hazards models were used to identify features associated with recurrence-free survival (RFS) and overall survival (OS). Features significant in both training sets were used to construct a grading system, which was then validated in a test set (n = 827, five institutions). Interobserver agreement was assessed among 10 pathologists on 25 cases. Results: Tumor budding (two-tier: cutoff at 10 buds per 0.785 mm<sup>2</sup>) was the only histologic feature significantly associated with both RFS and OS in multivariable analyses across both training sets. The proposed two-tier grading system—low-grade (0–9 buds), high-grade (≥10 buds)—was validated in the test set, demonstrating median RFS of 4.8 versus 1.6 years for low- versus high-grade tumors in the entire cohort and 7.2 versus 3.4 years within stage I patients. Interobserver agreement was moderate (Fleiss’ kappa = 0.524). Conclusions: The authors propose a simple, prognostically relevant grading system for resected invasive LUSC based on tumor budding. It is reproducible across international data sets and practical for routine pathology, offering a unified framework for clinical and research use. | |
| dc.identifier.citation | Journal of Thoracic Oncology (2025) | |
| dc.identifier.doi | 10.1016/j.jtho.2025.09.1761 | |
| dc.identifier.eissn | 15561380 | |
| dc.identifier.issn | 15560864 | |
| dc.identifier.pmid | 41038316 | |
| dc.identifier.scopus | 2-s2.0-105023889177 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/113502 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | A Grading System for Resected Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee | |
| dc.type | Article | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105023889177&origin=inward | |
| oaire.citation.title | Journal of Thoracic Oncology | |
| oairecerif.author.affiliation | Harvard Medical School | |
| oairecerif.author.affiliation | Mayo Clinic | |
| oairecerif.author.affiliation | Yale School of Medicine | |
| oairecerif.author.affiliation | University of Bern | |
| oairecerif.author.affiliation | Université Grenoble Alpes | |
| oairecerif.author.affiliation | Erasmus MC | |
| oairecerif.author.affiliation | University of Tsukuba | |
| oairecerif.author.affiliation | Centre Hospitalier Universitaire Vaudois | |
| oairecerif.author.affiliation | Yonsei University College of Medicine | |
| oairecerif.author.affiliation | University of Pittsburgh Medical Center | |
| oairecerif.author.affiliation | Universitätsspital Basel | |
| oairecerif.author.affiliation | St. Jude Children's Research Hospital | |
| oairecerif.author.affiliation | University of Memphis | |
| oairecerif.author.affiliation | Hospital Universitario 12 de Octubre | |
| oairecerif.author.affiliation | Royal Prince Alfred Hospital | |
| oairecerif.author.affiliation | Siriraj Hospital | |
| oairecerif.author.affiliation | Juntendo University School of Medicine | |
| oairecerif.author.affiliation | Università degli Studi di Torino, Scuola di Medicina | |
| oairecerif.author.affiliation | Institut Universitaire de Cardiologie et de pneumologie de Québec - Université Laval | |
| oairecerif.author.affiliation | Royal Brompton & Harefield NHS Foundation Trust | |
| oairecerif.author.affiliation | Shanghai Chest Hospital | |
| oairecerif.author.affiliation | Kyushu University Hospital | |
| oairecerif.author.affiliation | The Catholic University of Korea Yeouido St. Mary's Hospital | |
| oairecerif.author.affiliation | National Hospital Organization Ibarakihigashi National Hospital | |
| oairecerif.author.affiliation | International Association for the Study of Lung Cancer |
